Table 2. Detailed distributions of clinical and pathological characteristics between LPBC group and non-LPBC group.
| Variable | TILs level | χ2 | |
|---|---|---|---|
| HIGH | LOW | ||
| Age < 40 y | 32 (55%) | 60 (56%) | p.345 |
| Stage TNM | |||
| IIa | 22 (38%) | 29 (28%) | p.205 |
| IIb | 22 (38%) | 32 (30%) | |
| IIIa | 7 (12%) | 18 (17%) | |
| IIIb | 3 (5%) | 10 (9%) | |
| IIIc | 4 (7%) | 17 (16%) | |
| Histology | |||
| Ductal | 33 (57%) | 64 (60%) | p.060 |
| Lobular | 25 (43%) | 42 (40%) | |
| Grade 3 | 37 (64%) | 32 (30%) | p.005 |
| DCIS | 6 (10%) | 7(6%) | p.486 |
| LVI | 6 (10%) | 12 (11%) | p.106 |
| Ki67>50 | 50 (86%) | 90 (85%) | p.270 |
| NAC | |||
| Anthracycline+taxane | 47 (81%) | 98 (92%) | p.570 |
| pCR (ypT0/is, ypN0) | 51 (88%) | 10 (9%) | p.001 |
| ResidualTumor | |||
| Multifocal | 4 (7%) | 24 (22%) | p.001 |
| Conservative surgery | 39 (67%) | 43 (41%) | p.001 |
| Adjuvant Radiotherapy | 51 (88%) | 93 (88%) | p.754 |
| Quimioterapia adyuvante | 12 (21%) | 47(44%) | p.078 |